Johnson & Johnson’s Injectable Rybrevant Shows Promise in Extending Lives of Lung Cancer Patients

Johnson & Johnson’s injectable Rybrevant has shown promising results in extending the lives of lung cancer patients, with a 38% reduction in the risk of death compared to the intravenous version. The subcutaneous formulation demonstrated better overall survival, longer duration of response, and lower infusion-related reactions. With plans to file for FDA approval, J&J aims to gain a competitive edge in the market against AstraZeneca’s Tagrisso.